Patents by Inventor Xicai Huang
Xicai Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110071082Abstract: Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.Type: ApplicationFiled: April 13, 2010Publication date: March 24, 2011Inventors: Dominique P. Bridon, Michele Rasamoelisolo, Karen Thibaudeau, Xicai Huang, Richard Beliveau
-
Patent number: 7906482Abstract: The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.Type: GrantFiled: October 24, 2007Date of Patent: March 15, 2011Assignee: Advanced Diagnostics and DiscoveryInventors: Dominique P. Bridon, Roger Leger, Xicai Huang, Karen Thibaudeau, Martin Robitaille, Peter G. Milner
-
Patent number: 7741286Abstract: Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.Type: GrantFiled: February 8, 2006Date of Patent: June 22, 2010Assignee: ConjuChem Biotechnologies Inc.Inventors: Dominique P. Bridon, Michele Rasamoelisolo, Karen Thibaudeau, Xicai Huang, Richard Beliveau
-
Patent number: 7601691Abstract: The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.Type: GrantFiled: February 25, 2005Date of Patent: October 13, 2009Assignee: Conjuchem Biotechnologies Inc.Inventors: Dominique P. Bridon, Roger Leger, Xicai Huang, Karen Thibaudeau, Martin Robitaille, Peter G. Milner
-
Publication number: 20090054332Abstract: The present invention relates to compounds comprising modified thrombopoietin peptides and conjugates of such modified peptides to serum components, typically serum proteins or peptides. The compounds and conjugates of the invention comprise a reactive group or a residue of a reactive group, which is covalently attached to a modified peptide, optionally through a linking group. The present invention also provides methods for the covalent attachment of a modified peptide to a serum protein or peptide to form a conjugate of the invention. The conjugates of the invention typically exhibit a longer in vivo circulating half-life compared to the corresponding unconjugated peptides. The conjugates of the invention also retain at least some of the biological activity of the unconjugated peptides, and typically exhibit increased biological activity compared to the unconjugated peptides.Type: ApplicationFiled: June 21, 2008Publication date: February 26, 2009Applicant: CONJUCHEM BIOTECHNOLOGIES, INC.Inventors: Jean-Philippe Estradier, Martin Robitaille, Karen Thibaudeau, Dominique P. Bridon, Xicai Huang, Omar Quraishi, Nathalie Bousquet-Gagnon
-
Publication number: 20080194486Abstract: The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.Type: ApplicationFiled: October 24, 2007Publication date: August 14, 2008Applicant: CONJUCHEM BIOTECHNOLOGIES, INC.Inventors: Dominique P. Bridon, Roger Leger, Xicai Huang, Karen Thibaudeau, Martin Robitaille, Peter G. Milner
-
Publication number: 20080039532Abstract: The present application relates to a compound having a formula 1: B—R1-R2-M wherein B is a binding element for recognizing and binding a target; R1 is a first group of atoms for reacting with a functionality of the target so as to form a covalent bond with the target; R2 is a second group of atoms; R1 and R2 being such that the formation of the covalent bond between R1 and the target generates cleavage of the bond between R1 and R2 so as to free R2-M; and M is selected from the group consisting of a hydrogen atom and a pharmaceutically acceptable moiety. Alternatively, R1 and R2 can be inverted to form the formula II: B—R2-R1-M and being such that the formation of the covalent bond between R1 and the target generates cleavage of the bond between R1 and R2 so as to free R2-B.Type: ApplicationFiled: May 6, 2005Publication date: February 14, 2008Inventors: Dominique Bridon, Nathalie Bousquet-Gagnon, Xicai Huang, Omar Quraishi
-
Patent number: 7144854Abstract: Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.Type: GrantFiled: September 7, 2000Date of Patent: December 5, 2006Assignee: ConjuChem, Inc.Inventors: Dominique P. Bridon, Michele Rasamoelisolo, Karen Thibaudeau, Xicai Huang, Richard Beliveau
-
Publication number: 20060241019Abstract: The present invention relates to an insulin derivative comprising an insulin molecule and a reactive group for covalently bonding a blood component, wherein preferably the insulin molecule is human natural insulin molecule and the reactive group is coupled to an amino acid of the insulin molecule at a position selected from the positions Gly A1, Phe B1 and Lys B29.Type: ApplicationFiled: July 26, 2004Publication date: October 26, 2006Inventors: Dominique Bridon, Jean-Paul Castaigne, Xicai Huang, Roger Leger, Martin Robitaille
-
Publication number: 20060135428Abstract: Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.Type: ApplicationFiled: February 8, 2006Publication date: June 22, 2006Inventors: Dominique Bridon, Michele Rasamoelisolo, Karen Thibaudeau, Xicai Huang, Richard Beliveau
-
Publication number: 20050176643Abstract: The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.Type: ApplicationFiled: February 25, 2005Publication date: August 11, 2005Applicant: ConjuChem, Inc.Inventors: Dominique Bridon, Roger Leger, Xicai Huang, Karen Thibaudeau, Martin Robitaille, Peter Milner